Conference Track

Update on Investigational Agents in HCV: 2007

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Albinterferon Alfa-2b Plus Ribavirin for Chronic Hepatitis C Genotype 1 Achieves Comparable Efficacy to Peginterferon alfa-2a Plus Ribavirin With Fewer Injections
Short Duration VCH-759 Demonstrates Potent Antiviral Activity in HCV Genotype 1a and 1b Patients
HCV Polymerase Inhibitor R1626 Combined With PegIFN/RBV Results in > 80% of HCV Genotype 1 Patients Achieving RVR
Albinterferon alfa-2b Achieves SVR in Some Hepatitis C Patients Who Failed Previous Interferon-Based/Ribavirin Therapy
Multiple Infusions of Bavituximab Safe and Active Against HCV
Telaprevir Resistance Mutations Emerge Among Hepatitis C Patients Who Relapse Following Sequential Therapy of Telaprevir, Peginterferon alfa-2a, and Ribavirin
PROVE2 Study Shows High SVR Rates With Combination Treatment With Telaprevir, Peginterferon alfa-2a, and Ribavirin in Treatment-Naive Patients Infected With HCV Genotype 1
PROVE 1 Study: Combination Telaprevir, Peginterferon alfa-2a, and Ribavirin Therapy Has Rapid and Sustained Antiviral Activity in HCV Genotype 1 Patients
Peginterferon/Ribavirin/Nitazoxanide Increases Sustained Virologic Response Rate in Interferon-Naive HCV Genotype 4 Patients vs Peginterferon/Ribavirin
R7128, Promising Therapy for HCV Genotype 1 Nonresponders, Demonstrates Potent Antiviral Activity and Is Well Tolerated Over 14 days
GI-5005, a Yeast-Based Immunotherapy, Results in Dose-Dependent HCV-Specific Cellular Immune Responses and ALT Normalization in Chronic Hepatitis C Patients
HCV Polymerase Inhibitor R1626 Has High Genetic Barrier to Resistance With Potent Antiviral Effects in Chronic Hepatitis C
28 Days of Telaprevir, Peginterferon alfa-2a, and Ribavirin Followed by 44 Weeks of Peginterferon alfa-2a and Ribavirin Demonstrates Potent and Prolonged Antiviral Efficacy in Small Group of HCV Genotype 1 Patients
Biweekly Administration of Controlled-Release Recombinant Interferon alfa-2b Appears to Be Effective and Well Tolerated in Patients With HCV Genotype 1
Novel Nonnucleoside Polymerase Inhibitor GS-9190 Active and Well Tolerated in Treatment-Naive HCV Patients

Expert Analysis

Update on Investigational Agents in HCV: 2007

Faculty:
Nezam H. Afdhal, MD, FRCPI Ira M. Jacobson, MD David R. Nelson, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the safety and efficacy of novel therapies for HCV
Discuss recent studies regarding the development of resistance during treatment with novel HCV therapies
Explain the latest data on the optimal treatment duration for HCV therapies in development

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.5 contact hours (0.15 CEUs)

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.